文献速递乳腺乳腺X线

对比增强乳腺X线摄影作为MRI替代方案筛查乳腺癌:SCEMAM试验结果

Screening for Breast Cancer with Contrast-enhanced Mammography as an Alternative to MRI: SCEMAM Trial Results.
PubMed 文献 · Radiology · 2025-01-01

SCEMAM前瞻性试验纳入601名符合MRI筛查条件的女性,在数字乳腺断层合成(DBT)基础上加做对比增强乳腺X线摄影(CEM),CEM额外检出6例仅CEM可见的癌症(增量癌症检出率10.0/1000女性),但假阳性率从8.1%升至21.6%,联合AUC从0.73提高至0.92。

要点

  • CEM在DBT基础上额外检出6/601例癌症(10.0/1000女性,95%CI 3.3–18.3),其中5例浸润性均淋巴结阴性、中位大小0.7cm。
  • DBT联合CEM的假阳性率21.6%(127/589),较单用DBT的8.1%(48/589)增加13.4%(95%CI 10.8–16.4)。
  • 联合CEM后读者1的总体AUC由0.73升至0.92(P=.016),1年内无间期癌。

核心结论

  • 在DBT之后加做CEM可显著提高早期乳腺癌检出,虽大幅增加假阳性率,但使总体AUC提高0.19。

研究设计与样本

  • 前瞻性单臂筛查试验,2021年3月至2022年12月招募615名符合筛查MRI条件的女性,601名完成单次筛查CEM联合临床DBT,由两名放射科医师独立判读并以BI-RADS评估为参考。

诊断标准与关键数值

  • 增量癌症检出率为6/601即每1000名女性10.0例(95%CI 3.3–18.3);读者1的DBT联合CEM假阳性率127/589(21.6%),单用DBT为48/589(8.1%),增加13.4%(95%CI 10.8–16.4);读者1的联合AUC 0.92 vs 单用DBT 0.73(P=.016);读者1按CEM建议活检50/601(8.3%),其中6/50(12%)确诊癌症;病变水平仅由CEM触发的活检PPV3为7/62(11%)。

临床应用与阅片要点

  • 在符合MRI筛查条件的女性中,DBT加做CEM可检出仅CEM可见的早期浸润性癌(多为淋巴结阴性、体积小),但需注意假阳性率明显升高及活检推荐增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Many state laws require insurance coverage for supplemental screening MRI in women at elevated risk for breast cancer, but MRI capacity is limited. Purpose To evaluate the impact of contrast-enhanced mammography (CEM) on incremental cancer detection rate (ICDR), false-positive rate (FPR) due to recall, and positive predictive value of biopsies performed (PPV3) when added to digital breast tomosynthesis (DBT) in women eligible for screening MRI. Materials and Methods From March 2021 to December 2022, 615 eligible women were prospectively recruited and consented to a single screening CEM examination with clinical DBT. Two radiologists interpreted each imaging study: Reader 1 recorded DBT findings first, and reader 2 recorded CEM findings first. Incremental cancer detection rate, cancer type and/or nodal status, FPR, PPV3, interval cancer rate, and areas under receiver operating characteristic curve (AUCs) based on forced Breast Imaging Reporting and Data System assessments were evaluated. Results Six hundred one women (mean age, 56 years [range: 30-75 years]) completed CEM. Twelve of the 601 women (2.0%) were diagnosed with 16 malignant lesions; cancers in five of the 12 women (42%) were detected by reader 1 at DBT, and one was detected at DBT by reader 2 (also seen on CEM by both observers). Cancers in the other six women were identified only with CEM (ICDR, six per 601 or 10.0 per 1000 women [95% CI: 3.3, 18.3]): five had invasive disease, all node negative, with a median lesion size of 0.7 cm (range: 0.4-1.1 cm); three were lobular. The FPR of combined DBT plus CEM was 127 of 589 (21.6%) for reader 1, which was an increase of 13.4% (95% CI: 10.8, 16.4) over DBT alone at 48 of 589 (8.1%). Despite increased FPR, the addition of CEM improved the overall AUC for reader 1 to 0.92 versus 0.73 for DBT alone (P = .016). Among the 601 women, 50 (8.3%) were recommended for biopsy according to CEM by reader 1, and six of the 50 (12%) were diagnosed with cancer. At the lesion level, the PPV3 was seven of 62 (11%) for biopsies prompted only with CEM by reader 1. There were no interval cancers at 1 year. Conclusion A significant increase in the detection of early-stage breast cancer was achieved using CEM after DBT. Despite substantially increasing the FPR, adding CEM to DBT improved the overall AUC by 0.19. ClinicalTrials.gov registration no.: NCT04764292 © RSNA, 2025 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Berg WA, Vargo A, Lu AH, et al. Screening for Breast Cancer with Contrast-enhanced Mammography as an Alternative to MRI: SCEMAM Trial Results. Radiology. 2025. PMID: 40525975. doi:10.1148/radiol.242634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。